Citadel Advisors’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Citadel Advisors’s Portfolio GRTX Stock Details GRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-590,052	Closed	-$116K	–	15690
2023 Q4	$85.8K	Buy	+590,052	New	+$91.6K	﹤0.01%	11128
2023 Q3	–	Sell	-34,197	Closed	-$42.5K	–	15372
2023 Q2	$107K	Buy	+34,197	New	+$102K	﹤0.01%	10838
2023 Q1	–	Sell	-284	Closed	-$586	–	15761
2022 Q4	$423	Sell	284 -15,968	-98%	-$25.9K	﹤0.01%	14661
2022 Q3	$28K	Buy	16,252 +322	+2%	+$455	﹤0.01%	11947
2022 Q2	$21K	Sell	15,930 -122,654	-89%	-$210K	﹤0.01%	12394
2022 Q1	$330K	Buy	+138,584	New	+$361K	﹤0.01%	10371

Other funds holding GRTX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's GRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2024, closing a stake of 590,052 shares — an estimated $116K sold.

Citadel Advisors first reported a position in GRTX in Q1 2022 and held it in 6 quarters. The position peaked at $330K in Q1 2022. 36 funds tracked by Wall St. Rank hold GRTX as of Q1 2024.

Citadel Advisors reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 590,052 Galera Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $116K.
Citadel Advisors first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Citadel Advisors's Galera Therapeutics, Inc. Common Stock position peaked at $330K in Q1 2022.
36 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.